trending Market Intelligence /marketintelligence/en/news-insights/trending/7azk1FVcD2D6l84TQQtFLA2 content esgSubNav
In This List

Starpharma's VivaGel condom gets marketing approval in Japan

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Starpharma's VivaGel condom gets marketing approval in Japan

Starpharma Holdings Ltd. said the Japanese Pharmaceuticals and Medical Devices Agency granted it final approval to market its VivaGel condom.

The Australian company's commercial partner in Japan, Okamoto Industries Inc., plans to launch the product in the first half of 2019.

Starpharma will receive royalty payments under its license with Okamoto Industries, which holds the majority share of Japan's condom market, according to a news release.

The VivaGel condom is already approved for sale in Australia and Canada under the Lifestyles Dual Protect brand.

Recently, the U.S. Food and Drug Administration asked for confirmatory clinical data in order to approve the company's antibacterial gel VivaGel BV, a treatment for bacterial vaginosis, a common bacterial infection in women.